Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. The Company is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as Human Immunodeficiency Virus (HIV), Syphilis and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. The Company's manufacturing facilities are located in Halifax, Nova Scotia, Canada.


TSXV:MIR - Post by User

Comment by Biofinanaceon Jul 04, 2020 4:04pm
191 Views
Post# 31224616

RE:RE:Family Ctrld Comp

RE:RE:Family Ctrld CompAccording to Reffinitv : 
Medmira Holdings owns 72.01% X 658,364,320 (of outstanding shares ) = 474,088,147
Free Float ~ 28% i.e. 658,364,320 - 474,088,147 = 184,276,820 available for trading on TSX.

Such kind of structure is very sensitive to upside or downside swings.
I remember when I was avg @ .26 after CE approval the stock sky rocketed by 242% (.89) in just 4 days. Of course, when there is a bad news it wont take much time to go in opposite direction. 

As far as I know MIR (similar to other diagnostic companies I followed such as CODX) is very transparent in terms of its financials and for its updates. 

Financials we know was shared this week. 
In terms of updates -
1) March 16th - FDA revised its Serological tests spec (in terms of # of samples and protocol for verification of tests)
2) April 23rd - Announced Notification Submission to US FDA Emergency Use Authorization
3) May 21st - Medmira submits its EUA package

It can take anywhere 21 days to 45 days for FDA to give EUA permission (as FDA has to verify specs of the tests;  On June 4 FDA own verification of various tests seeking EUA - (https://open.fda.gov/apis/device/covid19serology/))

There are approx 200 companies seeking such approvals so it takes time. But if a company has CE mark then it brings some legitimacy to the package

As a trivia note - there is not a single Serological-Testing-Non-Legacy company (legacy comp being Seimens, Abbott etc) which is trading on TSX/NASDAQ/NYSE with an EUA. So valuation can be tricky for Medmira (I will share my valuation view in other post).

And I have been reading lately that people are comparing Medmira vs Sona which I believe is completely wrong. An antibody vs antigen detection comp. I love Sona (Esp in terms of return) becuase there is only one company approved for such a kind of test (Quidel) but given my scientific background I am not conviced that antigen presentation is so robust yet as compared to Ab (which is also a bit dicey) but given a choice I will first get an Ab testing. 

Hope this helps !


 
<< Previous
Bullboard Posts
Next >>